Does imatinib mesylate enhance therapeutic effects of gemcitabine in human malignant mesothelioma xenografts?
Imatinib mesylate enhances the therapeutic response to gemcitabine, in accordance with our previous in vitro data. These in vivo results validate imatinib mesylate and gemcitabine as a combination treatment of malignant mesothelioma, also in view of its known positive effects on tumor drug uptake. These evidences provide the rationale for the currently ongoing clinical trials.
Our research suggests that Plo12Ala polymorphism of PPARgamma may not be associated with the risk of developing ulcerative colitis in Japanese population.